Thymoglobulin®

also known as ATG

Investigated by: John Mascarenhas · Myeloproliferative Disorders-Research Consortium · National Cancer Institute (NCI) · National Institutes of Health (NIH)

today NCT00572897 · Ph 2

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00572897	Aug 2007 → Aug 2011	myelofibrosis	John Mascarenhas	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Thymoglobulin	“ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3” NCT00572897 ↗
Known as	ATG	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00572897 ↗
Route	Intravenous	“0.5 mg/kg IV on day -3” NCT00572897 ↗